Volume 27, Number 3—March 2021
Dispatch
Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection
Table 2
Positivity of antibodies to severe acute respiratory syndrome coronavirus 2 in 58 asymptomatic or mildly symptomatic patients at 8 mo after infection, South Korea*
Characteristic | Anti-N pan-Ig ECLIA, no. (%)† | Anti-N IgG ELISA, no. (%)‡ | Anti-S IgG ELISA, no. (%)§ | Anti-S1 IgG ELISA, no. (%)¶ | sVNT, no. (%)# |
---|---|---|---|---|---|
Total |
53/58 (91.4) |
15/58 (25.9) |
50/58 (86.2) |
40/58 (69.0) |
31/58 (53.4) |
Sex | |||||
M | 21/23 (91.3) | 1/23 (4.3) | 17/23 (73.9) | 11/23 (47.8) | 7/23 (30.4) |
F |
32/35 (91.4) |
14/35 (40.0)** |
33/35 (94.3)†† |
29/35 (82.9)** |
24/35 (68.6)** |
Age, y | |||||
<30 | 35/38 (92.1) | 5/38 (13.2) | 33/38 (86.8) | 25/38 (65.8) | 19/38 (50.0) |
>30 |
18/20 (90.0) |
10/20 (50.0)** |
17/20 (85.0) |
15/20 (75.0) |
12/20 (60.0) |
Duration of PCR positivity | |||||
<14 d | 3/6 (50.0) | 3/6 (50.0) | 4/6 (66.7) | 3/6 (50.0) | 2/6 (33.3) |
>14 d |
48/50 (96.0)** |
10/50 (20.0) |
44/50 (88.0) |
36/50 (72.0) |
27/50 (54.0) |
Disease severity | |||||
Asymptomatic | 7/7 (100) | 0/7 (0) | 5/7 (71.4) | 4/7 (57.1) | 4/7 (57.1) |
Mildly symptomatic | 46/51 (90.2) | 15/51 (29.4) | 45/51 (88.2) | 36/51 (70.6) | 27/51 (52.9) |
*Anti-N, antinucleocapsid; anti-S, antispike; anti-S1, antispike subunit; ECLIA, electrochemiluminescence immunoassay; pan-Ig, panimmunoglobulin; sVNT, surrogate virus neutralization test. †Roche Diagnostics (https://diagnostics.roche.com). ‡Epitope Diagnostics (https://www.epitopediagnostics.com). §InBios International (https://www.inbios.com). ¶Euroimmun (https://www.euroimmune.com). #GenScript (https://www.genscript.com). **p<0.01. ††p<0.05.
1These first authors equally contributed to this article.